Streetbeat News

RNXT

RenovoRx, Inc.

Industry

Biotechnology

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

RenovoRx has announced the enrollment of the first patient at the University of Nebraska Medical Center for its pivotal Phase III TIGeR-PaC clinical trial.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:35 pm

RenovoRx has published positive early-stage data on its TAMP therapy for locally advanced pancreatic cancer. The therapy, combined with prior chemoradiation, shows a 27-month overall survival rate. An ongoing Phase III trial is evaluating the targeted chemotherapy delivery. The study was published in The Oncologist.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:41 pm

The University of Nebraska Medical Center will enroll patients for RenovoRx's Phase III TIGeR-PaC clinical trial, which is focused on treating pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:34 pm

Ascendiant Capital has initiated coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:00 am

AMMO, Inc. (NASDAQ:POWW) shares fell over 19% despite reporting a profit and higher-than-expected sales for the fourth quarter. Other notable stock movements include significant gains for Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) and SRIVARU Holding Limited (NASDAQ:SVMH), and declines for QXO, Inc. (NASDAQ:QXO) and Nexalin Technology, Inc. (NASDAQ:NXL).

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 6:13 pm

The article highlights the performance of 12 health care stocks during Wednesday's after-market session. Notable gainers include Holdco Nuvo Group DG (NASDAQ:NUVO) with a 21.5% increase and Entero Therapeutics (NASDAQ:ENTO) with an 8.69% rise. Significant losers include Assure Holdings (NASDAQ:IONM) which fell by 38.4% and RenovoRx (NASDAQ:RNXT) which declined by 10.26%.

Portfolio Pulse from Benzinga Insights

June 12, 2024 | 8:31 pm

RenovoRx's CEO updated shareholders on the company's progress in Q1 2024, highlighting significant milestones, including $17.2 million raised, advancements in the Phase III TIGeR-PaC clinical trial, and the expansion of their TAMP therapy platform. Key management promotions and supportive research publications were also noted.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:42 pm

RenovoRx (NASDAQ: RNXT) announced the publication of pre-clinical studies that support the efficacy and drug delivery mechanism of its TAMP therapy platform. The studies show that TAMP increases intra-arterial pressure, leading to a 100-fold increase in local tissue concentration of the therapy, potentially improving efficacy, safety, and widening the therapeutic window of drugs. The data was published in the Journal of Vascular Interventional Radiology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:36 pm

RenovoRx, identified by its ticker RNXT, has successfully regained compliance with Nasdaq's listing requirements. This development is crucial for the company's continued listing on the exchange and may positively influence investor confidence and the stock's market performance.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 12:35 pm

RenovoRx has finalized a subscription agreement with accredited investors for an $11.1M private placement at market price, extending its cash runway into 2026. This financing will support the Phase III TIGeR-PaC trial and expand the TAMP clinical development pipeline into more cancer indications.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.